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Abstract
A longitudinal, prospective study was conducted intermittently in Norway, from 1999 to 2008, to investigate the Candida colonization
rates and species distributions in the tonsillopharyngeal and faecal ﬂora in: (i) children with cancer; (ii) children with cystic ﬁbrosis (CF);
and (iii) healthy children. The effect of antibiotic treatment on Candida colonization was also studied, and we looked for changes in anti-
fungal susceptibility over time within each child and between the different groups of children. In total, 566 tonsillopharyngeal swabs and
545 faecal samples were collected from 45 children with cancer, 37 children with CF, and 71 healthy, age-matched controls. The overall
colonization rate with Candida was not signiﬁcantly higher in the two groups of children undergoing extensive treatment with broad-
spectrum antibiotics than in healthy controls. Approximately one-third of the cancer patients had a total lack of Candida colonization or
had only one Candida-positive sample, despite multiple samples being taken, treatment with broad-spectrum antibiotics, long hospital
stays, and periods with neutropenia. Children with CF had the highest prevalence of Candida albicans. Amoxycillin, azithromycin, third-
generation cephalosporins and oral vancomycin resulted in a signiﬁcantly increased Candida colonization rate. Phenoxymethylpenicillin,
second-generation cephalosporins, metronidazole, trimethoprim–sulphamethoxazole, ciproﬂoxacin, penicillinase-resistant penicillins and
inhaled tobramycin or colistin showed minimal effects on the Candida colonization rate. We found no evidence of development of anti-
fungal resistance over time.
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Background
Children with cancer often undergo chemotherapy, causing
severe immunosuppression and neutropenia. Consequently,
they are at great risk for serious infections, including invasive
fungal infections. If there is any sign of febrile neutropenia,
they should be promptly treated with broad-spectrum antibi-
otics [1]. Diagnosis of a Candida infection in these patients is
difﬁcult. Blood cultures are often negative, and other diag-
nostic methods are unreliable. It has been shown that
patients with severe Candida infections are usually colonized
by Candida at multiple body sites [2–4]. Also, invasive Can-
dida infections regularly occur with the same genotypes as
those colonizing the patient [5,6].
Knowledge about the Candida ﬂora in children undergoing
repeated antibiotic treatment as compared with healthy chil-
dren is important, e.g. when considering treatment strategies
based on the use of surveillance cultures. Children with can-
cer receive more broad-spectrum antibiotics than most
other children. Likewise, children with cystic ﬁbrosis (CF)
receive large quantities of antibiotics, usually throughout
their lives [7]. Although children with CF have no particular
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risk for invasive yeast infections, some studies have shown
that airway colonization with Candida may cause symptoms
in CF patients [8].
As few studies have focused on the Candida ﬂora in differ-
ent categories of sick and healthy children, we have exam-
ined Candida colonization prospectively and longitudinally in
three groups: (i) children with cancer; (ii) children with CF;
and (iii) healthy children. The main aim was to investigate
and compare the Candida colonization rates and species dis-
tributions in the tonsillopharyngeal and faecal ﬂora. Subse-
quently, we studied the effect of antimicrobial treatment on
Candida colonization, and looked for changes in antifungal
susceptibility over time.
Materials and Methods
Subjects and clinical information
Serial tonsillopharyngeal swabs (n = 566) and faecal samples
(n = 545) were collected from 45 children with cancer at
Oslo University Hospital, Norway, during 1999–2000 and
2003–2005, from 37 children with CF at the paediatric out-
patient clinic, Oslo University Hospital, during 2004–2008,
and from 70 healthy children at day-care centres and schools
during 2000–2001 and 2006–2008. Inclusion criteria com-
prised newly diagnosed cancer that called for at least one
course of chemotherapy, a diagnosis of CF, and healthy sta-
tus with no underlying chronic disease. The number of sam-
ples within each group and time interval between ﬁrst and
last sample are shown in Table 1. For each sample, the
child’s parents were asked about previous antimicrobial
treatment. Hospital medical records for the children with
cancer and CF were reviewed for possible invasive fungal dis-
ease and information about all antimicrobial treatment in the
months before the ﬁrst sample and during the time of sam-
pling for each individual. Written, informed consent was
obtained from the subjects’ parents, and from the subjects
themselves when they were 12 years or older. The study
was reviewed by the Regional Ethics Committee of South-
East Norway.
Sampling, yeast identiﬁcation, and susceptibility testing
Tonsillopharyngeal swabs (both tonsils and the posterior
pharyngeal wall were swabbed) were put directly into trans-
port medium and plated within 5 h after collection. Stool
samples, mixed directly into Carey–Blair transport medium,
were plated within 5 days. The specimens were inoculated
onto Sabouraud dextrose agar containing antibiotics, and
incubated at 28C for a maximum of 5 days. From 2004,
CHROMagar Candida (Becton Dickinson, Sparks, MD, USA)
was also used. Yeast growth was semiquantitatively noted as
none, light (<10 colonies), moderate (10–50 colonies), or
heavy (>50 colonies). Morphologically distinct colonies were
picked for species identiﬁcation, performed at the Norwe-
gian Mycological Reference Laboratory, Oslo. Conventional
methods were used, e.g. colony colour on chromogenic agar,
germ-tube tests, microscopic morphology on corn-meal agar,
carbohydrate fermentation and assimilation, urease activity,
and morphology on Pal’s agar [9]. Additional identiﬁcation
methods, such as VITEK 2 (bio-Merie´ux, Marcy L’E´toile,
France), API 32C (bio-Merie´ux), an in-house 18S rDNA PCR
method, based on Turin et al. [10], and an in-house internal
transcribed spacer method based on Ahmad et al. [11], were
used when necessary. All non-albicans Candida strains and
TABLE 1. Background information and rates of Candida colonization in children with cancer, children with cystic ﬁbrosis (CF),
and healthy controls, Norway
Variablea (n = 45) Cancerb (A) (n = 45) CF (B) (n = 37) Controls (C) (n = 70)
p-valuesc
A vs. C B vs. C
Age (years) 5.3 (0–14) 6.8 (1–16) 6.1 (1–16) 0.30 0.39
Female sex 23 (51) 18 (49) 38 (54) 0.74 0.58
Indwelling central venous catheter 44 (98) 7 (19) 0 (0) <0.01 <0.01
Chronic lung infectiond 0 (0) 7 (19) 0 (0) ND <0.01
Invasive fungal disease 3 (6.7) 0 (0) 0 (0) ND ND
Time-spane 10.2 (3–22) 16.4 (7–33) 14.3 (3–26) <0.01 0.23
Tonsillopharyngeal swabs per individual 6.2 (1–13) 3.4 (3–6) 2.4 (1–4) <0.01 <0.01
Faecal samples per individual 6.3 (2–15) 2.9 (1–5) 2.5 (1–4) <0.01 0.03
Candida colonization, tonsillopharynxf 26 (59) 14 (38) 19 (27) 0.04 0.26
Candida colonization, faecesg 32 (71) 24 (73) 35 (52) 0.72 0.05
Candida colonization, either site 35 (78) 25 (68) 38 (54) 0.60 0.18
aContinuous data are presented as mean (range) and categorical data as number (%).
bDiagnoses: acute lymphoblastic leukaemia (n = 19), acute myeloblastic leukaemia (n = 6), non-Hodgkin’s lymphoma (n = 6), and various solid tumours (n = 14).
cWhen numbers were too small, the p-value was not determined (ND).
dPseudomonas aeruginosa (n = 4), Burkholderia cephacia (n = 2), atypical mycobacterium (n = 1).
eMean number of months between ﬁrst and last sample; four controls missing as they provided only one set of samples.
fNumber of children with at least one Candida-positive tonsillopharyngeal swab (one child with cancer did not provide samples).
gNumber of children with at least one Candida-positive faecal sample (four children with CF and three healthy controls did not provide samples).
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some Candida albicans strains were re-examined with matrix-
assisted laser desorption ionization time-of-ﬂight mass spec-
trometry [12] in 2010.
The Candida isolates were collectively tested, in a blinded
fashion, for antifungal susceptibility with the Etest method
(bio-Merie´ux). Only the ﬁrst and the last isolates were
tested when a child provided more than two positive cul-
tures with the same species.
Analysis of antibiotic effect
All samples were examined individually to look for differ-
ences in the rates of Candida colonization according to the
type of antibiotic used: (i) we included samples taken during
antibiotic treatment of a minimum of 3 days in duration, and
samples were included up to 5 days after antibiotic treat-
ment was stopped; (ii) we excluded samples taken after 1–
2 days of antibiotic treatment and samples where antibiotic
treatment had been stopped for only 6–20 days, to ensure
that samples with unknown antibiotic effects were not used;
and (iii) we excluded all samples taken during antifungal
treatment, or <21 days after antifungal treatment had been
stopped, to avoid antifungal inﬂuence.
Statistics
SPSS software (version 18.0) was used for all statistical analy-
ses. For comparison of categorical variables in different
groups, the Pearson chi-square test was used. For compari-
son of continuous variables in two different groups, an inde-
pendent-samples t-test was used. As the number of samples
per individual in the cancer group was much greater than in
the two other groups, we used linear regression to adjust
for number of samples. A 5% signiﬁcance level was used.
Results
Background information and Candida colonization rates are
presented in Table 1. The rate of Candida colonization was not
different between the 31 children with haematological cancer
and the 14 children with solid tumours (p 0.93), between
females and males (p 0.48), or between the two time periods
for sampling (p 0.80). The mean age was similar for the colo-
nized (5.9 years) and non-colonized (6.3 years) children
(p 0.59). The rate of heavy Candida load is shown in Table 2.
Three (6.6%) cancer patients suffered invasive fungal infec-
tions: one patient with C. albicans candidaemia; one patient
with C. tropicalis candidaemia and radiological changes com-
patible with hepatosplenic candidiasis; and one patient who
had ultrasonographic and magnetic resonance imaging ﬁnd-
ings indicative of disseminated fungal infection with lesions in
the brain and liver, although blood cultures were negative.
No invasive yeast infections occurred in the children with
CF or the healthy controls.
The species distribution among the Candida-positive chil-
dren is shown in Table 3. Most of the children had a stable
ﬂora over time, and colonization with two different Candida
species was common (data not shown). In the cancer group,
six (13%) children, with a total of 9–19 samples, had no sam-
ples positive for Candida, and seven (16%) children, with a total
of 9–17 samples, had only one sample positive for Candida.
Antibiotic consumption and Candida colonization
All children with cancer and CF received antibiotic treatment
during the observation period (Table 4). Only six (8.6%)
healthy controls were treated with antibiotics less than
40 days prior to sampling (oral phenoxymethylpenicillin or
amoxycillin). Thirty-ﬁve (50%) healthy children had never
received antibiotics.
TABLE 2. Rate of heavy Candida load in the Candida-
positive children with cancer, children with cystic ﬁbrosis
(CF), and healthy controls, Norway
Sitea
Cancer
(A) (%)
CF
(B) (%)
Controls
(C) (%)
p-values
A vs. B A vs. C B vs. C
Tonsillopharynx 32 7.1 24 0.01 0.51 0.11
Faeces 36 58 25 0.04 0.19 0.02
aOverall, the rate of heavy Candida load was signiﬁcantly higher in the faeces
(37%) than in the tonsillopharynx (23%, p 0.04).
TABLE 3. Candida species distribution in the Candida-
positive children with cancer, children with cystic ﬁbrosis
(CF), and healthy controls, Norwaya
Candida
species
Cancer
(A)
(n = 35)
CF
(B)
(n = 25)
Controls
(C)
(n = 38)
p-valuesb
A vs. B A vs. C B vs. C
C. albicans 22 (63) 23 (92) 27 (71) 0.09 0.46 0.04
Non-albicans
Candida
20 (57) 8 (32) 18 (47) 0.89 0.40 0.23
C. parapsilosis 16 (46) 1 (4.0) 11 (29) 0.04 0.14 0.01
C. lusitaniae 2 (5.7) 1 (4.0) 3 (7.9) ND ND ND
C. dubliniensis 4 (11) 1 (4.0) 0 (0) ND ND ND
C. krusei 0 (0) 3 (12) 1 (2.6) ND ND ND
C. tropicalis 2 (5.7) 1 (4.0) 0 (0) ND ND ND
C. famata 1 (2.9) 1 (4.0) 0 (0) ND ND ND
C. guilliermondii 2 (5.7) 0 (0) 0 (0) ND ND ND
C. magnoliae 2 (5.7) 0 (0) 0 (0) ND ND ND
C. sphaerica 0 (0) 0 (0) 2 (5.3) ND ND ND
Pichia
guilliermondii
complexc
1 (2.9) 0 (0) 1 (2.6) ND ND ND
Other Candida
spp.d
0 (0) 0 (0) 2 (5.3) ND ND ND
aNumber (%) of children with at least one positive culture.
bOwing to small numbers, many of the p-values were not determined (ND).
cOriginally identiﬁed as C. famata and C. guilliermondii. Internal transcribed spacer
results listed them as possible Meyerozyma caribbica/Pichia caribbica/Candida
carpophila/Candida fukuyamensis.
dC. intermedia (n = 1), C. pulcherrima (n = 1).
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We found no or minimal effect on Candida colonization of
phenoxymethylpenicillin, second-generation cephalosporins,
metronidazole, trimethoprim–sulphamethoxazole, ciproﬂoxa-
cin, cloxacillin, dicloxacillin, or inhaled tobramycin or colistin.
Meropenem was always used in combination with other
agents, and was consequently not included in the analyses.
Amoxycillin, azithromycin, third-generation cephalosporins
and oral vancomycin were predisposing antibiotics (PAs)
for Candida colonization. In the tonsillopharynx, the chil-
dren on a PA had signiﬁcantly higher Candida colonization
rates (11/19) than those without antibiotics (26/129,
p <0.01) and those on antibiotics other than a PA (6/29,
p 0.01). In faeces, children on a PA had signiﬁcantly higher
Candida colonization rates (17/21) than those without anti-
biotics (46/119, p <0.01) but not compared with the children
on other antibiotics (15/24, p 0.18). Children on a PA had
signiﬁcantly more samples with a heavy Candida load in fae-
ces (11/17) than children without antibiotics (16/46, p 0.03).
The difference in heavy load was non-signiﬁcant in the ton-
sillopharynx (p 0.98).
The use of antifungals is shown in Table 4. In the cancer
group, we observed no signiﬁcant decrease in Candida colo-
nization rates in the 13 children on oral nystatin prophylaxis
as compared with the remaining 32. Twenty tonsillopharyn-
geal swabs and 26 faecal samples were collected during
ongoing systemic antifungal treatment from 11 and nine chil-
dren, respectively. We found no signiﬁcant difference in Can-
dida colonization rates between these samples and the
samples from cancer patients without antifungal treatment. A
change in Candida species after antifungal treatment was
observed in three children. Only one acquired a more resis-
tant species (Candida guilliermondii).
Antifungal susceptibility
The MIC values for the different Candida isolates from this
study are shown in Table 5. The susceptibility did not change
over time in any of the children. The MIC values for ﬂuco-
nazole-sensitive Candida isolates were similar between the
sampling periods and between the three study groups of chil-
dren. Nine children carried a ﬂuconazole-resistant Candida
strain: ﬁve (11%) children with cancer (C. guilliermondii, Can-
dida magnoliae, Pichia guilliermondii complex), three (8.1%)
children with CF (Candida krusei), and one (1.4%) healthy
control (C. krusei). Only one (2.2%) child with cancer and
one (2.7%) child with CF carried an amphotericin-resistant
organism (Candida famata).
TABLE 4. Antibiotic and antifungal consumption during the study period in the study groups of children with cancer and
children with cystic ﬁbrosis (CF), Norwaya
Type of antimicrobial
Cancer (n = 45) CF (n = 37)
p-valueNo. (%) of individuals Mean no. (range) of courses No. (%) of individuals Mean no. (range) of courses
Phenoxymethylpenicillin 6 (13) 1.2 (1–2) 10 (27) 1.3 (1–2) 0.12
Amoxycillin 5 (11) 1.0 (1) 24 (65) 2.3 (1–7) <0.01
Ampicillin 38 (84) 3.6 (1–9) 1 (2.7) 1.0 (1) <0.01
Dicloxacillin or cloxacillin 12 (27) 1.2 (1–2) 17 (46) 3.1 (1–10) 0.07
Second-generation cephalosporins 21 (47) 1.5 (1–3) 23 (62) 2.7 (1–14) 0.16
Third-generation cephalosporinsb 29 (64) 2.6 (1–8) 12 (32) 1.8 (1–5) <0.01
Meropenem 8 (18) 1.3 (1–3) 5 (14) 2.2 (1–5) 0.60
Aminoglycosides 38 (84) 3.7 (1–10) 15 (41) 2.3 (1–6) <0.01
Vancomycin 19 (42) 2.1 (1–5) 0 (0) 0 <0.01
Oral vancomycinc 2 (4.4) 1.5 (1–2) 0 (0) 0 ND
Metronidazole 24 (53) 2.3 (1–6) 0 (0) 0 <0.01
Trimethoprim–sulphamethoxazoled 38 (84) ND 25 (68) ND 0.07
Azithromycin 0 (0) 0 15 (41) ND <0.01
Erythromycin 6 (13) 1.0 (1) 0 (0) 0 0.02
Clindamycin 2 (4.4) 2.0 (2) 13 (35) 1.5 (1–3) <0.01
Ciproﬂoxacin 0 (0) 0 13 (35) 2.7 (1–8) <0.01
Inhaled tobramycin or colistin 0 (0) 0 14 (38) ND <0.01
Other antibiotics 4 (16) 1.0 (1) 6 (16) ND 0.31
Fluconazolee 22 (49) 2.1 (1–7) 0 (0) 0 <0.01
Amphotericin B 8 (18) 1.5 (1–5) 1 (2.7) 1.0 (1) 0.03
Voriconazolef 2 (4.4) 1.0 (1) 1 (2.7) 1.0 (1) 0.68
Caspofungin 0 (0) 0 1 (2.7) 1.0 (1) ND
Mycostatin 20 (44) ND 0 (0) 0 <0.01
aNumber (no.) of individuals with at least one course of treatment, and mean no. (range) of courses per individual. Treatment for less than 2 days was excluded. When both
short courses and long-term treatment and/or prophylaxis were included, the number of courses per individual was not determined (ND). Owing to small numbers, some of
the p-values were not determined (ND).
bCeftazidime, cefotaxime and ceftriaxone in the cancer group; only ceftazidime in the CF group.
cTwo children were treated with oral vancomycin, owing to prolonged hospital-acquired diarrhoea (Clostridium difﬁcile).
dTrimethoprim alone (n = 6) is included. In the cancer group, 31 of the children received oral trimethoprim–sulphamethoxazole on 2 or 3 days per week (Pneumocystis
jirovecii prophylaxis).
eFour of the children received several months of ﬂuconazole treatment.
fAll three children received more than 2 months of voriconazole treatment.
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Discussion
A striking result of this study, comprising 1111 samples, is
that the overall Candida colonization rate was not signiﬁ-
cantly higher in the two groups of children undergoing
extensive treatment with broad-spectrum antibiotics than in
the healthy controls, who received minimal or no antibiotic
treatment. This was unexpected, as treatment with broad-
spectrum antibiotics is generally regarded as a predisposing
factor for increased colonization by Candida. Many studies
have found higher colonization rates in patients than in
healthy individuals [13]. However, longitudinal studies are
scarce. Agirbasli et al. [14] found that the colonization rate
among 80 hospitalized children with repeated sampling was
higher than in 61 healthy control children sampled only once.
However, the lack of multiple samples in the control group
may have led to an underestimation of the rate of coloniza-
tion in these children. In our study, the only signiﬁcant differ-
ences found were higher Candida colonization rates in the
faeces of children with CF and in the tonsillopharynx of chil-
dren with cancer than in the healthy controls. Interestingly,
13% of children with cancer and repeated episodes of neu-
tropenia, broad-spectrum antibiotic treatment, long hospital
stays and multiple samplings for Candida colonization
remained negative, and 16% had only one positive sample.
This strongly suggests that there are individual mechanisms
contributing to Candida colonization resistance.
Several molecular studies have shown that gastrointestinal
colonization with Candida precedes invasive disease [5,6,15].
In our study, the prevalence of documented invasive fungal
infections was only 6.6%. The two children with candidae-
mias had the same species in their blood culture as in their
tonsillopharynx and/or faeces, suggesting a common origin.
Although controversial, surveillance cultures may be of great
value in high-risk patients if used appropriately [2–4,16]. Our
study shows that children with cancer are often colonized
with Candida. Thus, an isolated Candida-positive oropharyn-
geal or faecal sample does not call for antifungal treatment.
However, one might consider collecting surveillance cultures
from certain high-risk children, e.g. prior to certain chemo-
therapy courses that regularly cause severe mucositis and
prolonged neutropenia.
Candida colonization varies with the type of antibiotic
used. This has been shown in human and mouse studies [17–
20]. Children were investigated in one small study [21]. Anti-
biotics with a high level of biliary excretion, suppression of
anaerobes and a broad spectrum of action tend to promote
faecal overgrowth of yeasts. We were able to analyse more
than 1000 samples from 172 children with detailed informa-
tion about antibiotic and antifungal treatment. We identiﬁed
some antibiotics, including amoxycillin, azithromycin, third-
generation cephalosporins, and oral vancomycin, that seemed
to have a much greater impact on the Candida colonization
rates in the faeces and tonsillopharynx than other agents.
Our semiquantitative results suggested that these agents also
caused a heavier Candida load than no antibiotic treatment in
the faecal ﬂora. This is an important ﬁnding, as a heavy Can-
dida load has been associated with risk of invasive disease
[3,16].
The use of nystatin prophylaxis and other antifungal agents
did not signiﬁcantly reduce Candida colonization among our
patients, as shown previously [22,23]. Some anticancer
agents, e.g. cyclophosphamide and dexamethasone, have been
shown to increase Candida colonization in mouse models
[24,25]. Many of our cancer patients were treated with these
TABLE 5. In vitro antifungal susceptibility in Candida isolates
from children with cancer, children with cystic ﬁbrosis (CF),
and healthy controls, Norway
Species
(no. of isolates)
Antifungal
agent
MIC range
(mg/L)
MIC50
(mg/L)
MIC90
(mg/L)
%
Resistanta
C. albicans (121) FLC 0.064–0.5 0.25 0.25 0
C. parapsilosis (40) FLC 0.125–1 0.25 0.5 0
CAS 0.25–1 0.5 0.5 0
C. dubliniensis (8) FLC 0.125–1 0.25 0.5 ND
C. lusitaniae (7) FLC 0.25–1 1 1 ND
CAS 0.25–0.5 0.25 0.5 ND
AMB 0.032–0.064 0.064 0.064 0
C. tropicalis (5) FLC 0.5 0.5 0.5 0
CAS 0.125 0.125 0.125 0
AMB 0.25–0.5 0.25 0.5 0
C. krusei (4) FLC 16–32 16 32 100
CAS 0.5–1 0.5 1 50
AMB 0.25–0.5 0.5 0.5 0
C. guilliermondii (3) FLCb 8–32 32 32 ND
CAS 0.25–0.5 0.5 0.5 ND
AMB 0.032 0.032 0.032 0
Pichia guillermondii
complex (2)
FLCb 1–8 ND
CAS 0.5 ND
AMB 0.064–0.25 0
C. famata (2) FLC 0.25–4 ND
CAS 0.25–0.25 ND
AMB >32 100
C. magnoliae (2) FLC >256 ND
CAS 0.25–0.5 ND
AMB 0.064–0.125 0
C. sphaerica (2) FLCb 0.25–2 ND
CAS 0.25–0.5 ND
AMB 0.25 0
C. intermedia (1) FLC 0.5 ND
CAS 0.5 ND
AMB 0.5 0
C. pulcherrima (1) FLC 0.5 ND
CAS 0.5 ND
AMB 0.016 0
AMB, amphotericin B; CAS, caspofungin; FLC, ﬂuconazole.
aClinical breakpoint (CBP) for FLC resistance according to EUCAST [28]:
>4 mg/L for C. albicans, C. parapsilosis, and C. tropicalis; C. krusei is considered to
be intrinsically resistant. CBP for CAS resistance according to the CLSI [29]:
>0.5 mg/L for C. albicans, C. krusei, and C. tropicalis, and >4 mg/L for C. parapsilo-
sis. The AMB breakpoint was set to resistance >1 mg/L, according to the EU-
CAST tradition. For several species, the CBP has not been determined (ND).
bAll three C. guilliermondii isolates, one isolate from the C. guilliermondii complex
and one C. sphaerica isolate showed heteroresistance to FLC. Only the highest
MIC value is reported.
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and other antineoplastic agents for several months. Thus,
anticancer drugs may have contributed to an increased Can-
dida colonization in our children with cancer.
C. albicans was the most frequent species in all study
groups, and this correlates well with the species distribution
in the Norwegian Candidaemia Registry [26,27]. The preva-
lence of C. albicans was especially high in the CF group. In
Norway, ﬂuconazole resistance in C. albicans is rare [26,27].
In our study, we found no evidence of an increase in antifun-
gal drug resistance over time. The MIC values seemed to be
stable within each individual, there were no apparent differ-
ences in susceptibility between 1999 and 2008, and we found
no signiﬁcant differences between the children with cancer,
the children with CF, and healthy controls. Clinical break-
points for ﬂuconazole are not given for all species [28].
However, we found three C. guillermondii isolates, one isolate
from the C. guilliermondii complex and two C. magnoliae iso-
lates with reduced ﬂuconazole susceptibility, in addition to
four C. krusei isolates with intrinsic resistance. Only one child
with cancer had a species shift that could have been caused
by antifungal treatment: after several courses of ﬂuconazole,
a change from a ﬂuconazole-susceptible C. albicans isolate to
a ﬂuconazole-resistant C. guilliermondii isolate was observed.
In the four children who received months of ﬂuconazole
and/or voriconazole treatment, we found no colonization
with resistant Candida species. The two children who were
colonized with an amphotericin B-resistant C. famata isolate
had never received antifungal treatment. Caspofungin was
used in only one child with CF. The susceptibility data sug-
gest that most of our isolates were susceptible to caspofun-
gin, with MICs within their epidemiological cut-off values
[29]. However, all four C. krusei isolates had higher MICs
than the epidemiological cut-off value (0.25 mg/L). Whether
this has any clinical importance is uncertain.
There are some weaknesses of this study. The relatively
low number of children may cause some difﬁculties in deter-
mining signiﬁcant differences, although multiple samples per
individual partially compensates for the relatively low number
of subjects. Also, the sampling spanned a 9-year period.
There have been some changes in methods, e.g. the inclusion
of a chromogenic agar, which makes it easier to detect
mixed cultures. Finally, methods other than tonsillopharyn-
geal swabs may be more sensitive in determining the rate of
Candida colonization in the oropharynx [13,30].
In conclusion, in this extensive longitudinal study, we
found that both sick children undergoing repeated broad-
spectrum antibiotic therapy and healthy children exposed to
little or no antibiotic treatment are often colonized with
Candida species. Most of the children had stable colonization
over time with only one or two species. In addition, some
children seemed to be almost resistant to Candida coloniza-
tion, independently of antibiotic treatment and underlying
disease. Amoxycillin, azithromycin, third-generation cephalo-
sporins and oral vancomycin seem to increase both the rate
and load of Candida colonization. We found no evidence of
antifungal resistance development over time.
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